Entrada Therapeutics Inc 2025年度报告

FORM 10-K (Mark One) For the transition period from to Commission File Number: 001-40969ENTRADA THERAPEUTICS, INC. Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or forsuch shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of thischapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See thedefinitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accountingstandards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting underSection 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error topreviously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executiveofficers during the relevant recovery period pursuant to §240.10D-1(b). Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ The aggregate market value of registrant’s common equity held by non-affiliates of registrant on June 30, 2025 was approximately $191.2 million based upon the closing sale price of thecommon stock as reported on The Nasdaq Global Market as of June 30, 2025. In determining the market value of non-affiliate common stock, shares of the registrant’s common stockbeneficially owned by officers, directors and affiliates have been excluded. This determination of affiliate status is not necessarily a conclusive determination for other purposes. As of February 19, 2026, the registrant had 38,284,313 shares of common stock, $0.0001 par value per share, outstanding. DOCUMENTS INCORPORATED BY REFERENCE TABLE OF CONTENTS PART I Item 1.BusinessItem 1A.Risk FactorsItem 1B.Unresolved Staff CommentsItem 1C.CybersecurityItem 2.PropertiesItem 3.Legal ProceedingsItem 4.Mine Safety Disclosures PART II Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases ofEquity Securities111Item 6.Reserved111Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations111Item 7A.Quantitative and Qualitative Disclosures About Market Risk122Item 8.Financial Statements and Supplementary Data123Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure153Item 9A.Controls and Procedures153Item 9B.Other Information153Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections154 PART III Item 10.Directors, Executive Officers and Corporate Governance155Item 11.Executive Compensation155Item 12.Security Ownership of Certain Beneficial Owners and Management and Related StockholderMatters155Item 13.Certain Relationships and Related Transactions, and Director Independence155Item 14.Principal Accounting Fees and Services155 PART IV Item 15.Exhibits and Financial Statement SchedulesItem 16.Form 10-K SummarySignatures 156158159 From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/entradatx to distribute materialinformation. Our financial and other material information is routinely posted to and accessible on the Investors Relations section of ourwebsite, available at www.entradatx.com. Investors are encouraged to review the Investors Relations section of our website becausewe may post material information on that site that is not otherwise disseminated by us. Information that is contained in